HOME ABOUT CONTACT AVAILABLE ISSUES SUBSCRIBE MEDIA & ADS
LATEST UPDATES » Vol 26, Nos. 07 & 08, July & August 2022 – Engineering a Sustainable Future       » Improving Crop Yield With Leaf Angles       » Combatting Tumours at the Gut With Novel Oral Vaccine Made by Bacteria Robot       » New Carbon Capture System With Record-Breaking Efficiency to Revolutionise Direct Air Capture       » Simulating the Synergistic Interactions of Neurons and Synapses in Computing Devices       » Understanding Gene Functions: From Algae to Plants       » Colour-Modified Mice Tissues Allow for Higher-Resolution Imaging      
Vol 22, No. 01, January 2018   |   Issue PDF view/purchase
EYE ON CHINA
Eisai's Aricept approved for additional indication of severe Alzheimer's disease in China
Aricept is the first Alzheimer's disease treatment with a broad indication that covers mild to severe Alzheimer's disease in China.

Eisai Co., Ltd. announced that Aricept (donepezil hydrochloride) has been approved for the additional indication of severe Alzheimer's disease in China. Aricept is the first Alzheimer's disease treatment with a broad indication that covers mild to severe Alzheimer's disease in China.

The approval of the additional indication was based on the results of a Phase III clinical study (Study 3391) in China. Study 339 was a multi-center, randomized, double-blind, placebo controlled, parallel-group study to evaluate the efficacy and safety of Aricept 10 mg per day in 313 Chinese patients with severe Alzheimer's disease. In this study, Aricept demonstrated a statistically significant improvement in total Severe Impairment Battery scores after 24 weeks compared to placebo, which was the primary endpoint of the study. In the study, the four most commonly observed adverse events in the Aricept arm were bradycardia, anorexia, QT interval prolongation, and dizziness.

In China, it has been estimated that approximately 6 million people suffer from Alzheimer's disease. Furthermore, with the progressive aging of the population, the number of patients with dementia is expected to greatly increase in the future.

With the approval of this indication covering severe Alzheimer's disease, Eisai strives to further contribute to increasing the quality of life of patients with Alzheimer's disease in China, and as the originator of Aricept, continues to make comprehensive contributions in dementia such as improving treatment and care, increasing public awareness of the disease and discovering new treatment methods.

FORTHCOMING ISSUE  
MGI Makes Possible New Advances in Agrigenomics Research and Molecular Breeding
NEWS CRUNCH  
news Medtec China 2022 Gathers Medtech Leading Enterprises, Optimising Medical Equipment Supply Chain by Creating Online-Offline Promotion Platforms
news Medtec China 2022 Is Now Open for Visitor Registration, Helping Medical Device Manufacturers in Medtech Sourcing and Supply Chain Stabilisation
news Inaugural Asia Summit on Global Health highlights Hong Kong's advantages
news Asia Summit on Global Health (ASGH) 2021 — Shaping a Resilient and Sustainable Future
SPOTLIGHT  

MAGAZINE TAGS
About Us
Events
Available issues
Editorial Board
Letters to Editor
Contribute to APBN
Advertise with Us
CONTACT
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» For Editorial Enquiries:
   [email protected] or Ms Carmen Chan
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
   [email protected]
Copyright© 2022 World Scientific Publishing Co Pte Ltd  •  Privacy Policy